Treatment of newly diagnosed transplant ineligible multiple myeloma: is there a BENEFIT to adding bortezomib to the standard backbone?
@article{ACTR10940, author = {Issam S. Hamadeh and Barry Paul}, title = {Treatment of newly diagnosed transplant ineligible multiple myeloma: is there a BENEFIT to adding bortezomib to the standard backbone?}, journal = {AME Clinical Trials Review}, volume = {3}, number = {0}, year = {2025}, keywords = {}, abstract = {}, issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/10940} }